Method for treating adhesive abdominal disease in children
FIELD: medicine, juvenile surgery.
SUBSTANCE: the method is characterized by the fact that 3 wk before surgical dissection of adhesions due to laparoscopy one should prescribe bifiform per 1 capsule and Hilak-Forte per 10-15 drops thrice daily. Moreover, 7 d before surgical interference it is necessary to conduct 7 seances of electrophoresis with irucsol and prescribe smekta sorbent per 1 packet thrice daily. Then comes laparoscopic dissection of adhesions, and after surgical interference one should perform electrophoresis with irucsol for 7 d. After appearance of intestinal peristaltics it is necessary to apply smekta per 1 packet thrice daily for 7 d. Since the 8th after operation one should prescribe bifiform per 1 capsule and Hilak-Forte per 10-15 drops thrice daily for 1 mo. Then 1 mo after laparoscopy one should prescribe electrophoresis with collalysine up to 8-10 procedures at simultaneous abdominal massage and curative-physical culture complex for 8-10 d. The method enables to obtain antiadhesive effect in 92% cases of surgical dissection of adhesions due to complex impact upon pathogenesis of adhesive disease, at decreased number of relapses.
EFFECT: higher efficiency of therapy.
The invention relates to medicine, namely to pediatric surgery.
At the present time the problem of adhesive disease (SA) of the abdominal cavity is the most relevant in surgery. Adhesions after operations on the abdominal organs occur in 80-90% of cases and the number of diseases in the soil adhesions of the stomach varies from 12 to 64% of cases. SAT peritoneum in the form of acute and chronic intestinal obstruction occurs in 57% of cases. Among patients hospitalized in surgical hospital with a diagnosis of acute adhesive intestinal obstruction (oscn), the proportion of patients with spaece-dynamic intestinal obstruction varies 45-87%.
SAT in 50-75% completed oscn requiring emergency surgical intervention. Recurrence SB reaches 30-60% and exacerbating the condition of the patients, leading to fatal outcomes in 13-55% of cases.
The increase in the number of surgical procedures in the abdominal cavity and the growing number of adhesive complications challenged surgeons problem - to prevent the formation of postoperative adhesions.
Proposed numerous methods of treatment and prevention of SB abdominal cavity allow you to get antiadhesive effect in 20-65% of cases. However, the proposed treatment schemes have the disadvantage in the individual treatment of each case SAT.
The prototype of the proposed CSP is both the author proposes a method for the treatment of adhesive disease of the abdominal cavity in children, belonging to the group of “fast acetylators”, with an average speed of acetylation 89,75+0,61% at the rate of 75% and with inadequate cooperative cell response (braking output of macrophages, increased amounts of fibrin).
The method consists in assigning to laparoscopic division of adhesions in the abdominal cavity adjuvant therapy, including anti-inflammatory drugs, use of complexing compounds D - penitsillamin in a dosage of age 12-18 days in combination with phonophoresis proteolytic enzyme iruxol or electrophoresis proteolytic enzyme kulalisena on the anterior wall of the abdomen. Then is carried out in a planned manner laparoscopic division of adhesions. The latter has become friable, easily separated from the peritoneum that provide safe separation during laparoscopy. Comprehensive protivospaechnyj the treatment was performed only children with adhesive disease of the abdominal cavity from a group of “fast acetylators”. In the group of “slow acetylators” treatment D - penitsillaminom not performed, performed only endoscopic division of adhesions. All children are “rapid acetylators” after the complex treatment was under surveillance from 1 year to 4 years, recurrence adhesive disease is not checked / MARINA Ivanova, Konovalov, A., Sergeev A.V., Gordeeva I.P., who Solovieva H., Tsvetkova E.I. Alekseeva N.A. Pathogenetic treatment of adhesive disease in children.// Russian journal of Perinatology and Pediatrics. - 1996. Volume 41. No. 4. - P.64/.
In our opinion this method has some drawbacks: it is not applicable in all children with adhesive disease of the abdominal cavity, but only for children in the “fast acetylators”, to identify this group of children needed more time-consuming laboratory tests, complex-forming compound D - penicillamine toxic - possible: leukopenia, thrombocytopenia, agranulocytosis, proteinuria, hematuria, disorder of the gastrointestinal tract, myalgia, arthralgia, pruritus, urticaria. When it is used to monitor the morphological picture of the blood after 3 days, to measure body temperature, and control the content in the urine copper / Mashkovsky PPM Medicines. The textbook of pharmacotherapy for physicians. - 1988. - part 2. - S-188/.
The author proposes a method for the treatment of adhesive disease of the abdominal cavity in children, including laparoscopic dissection of adhesions, normalization biocenose intestinal probiotics by Bifiform and hilak-Forte, the purpose of the sorbents in the form of receiving smecta, physiotherapy in the form of elecrophoresis with proteolytic enzymes iruxol and collision, belly massage and exercise therapy in the form of walk - Proprieta, and then high in the accepting of the knees; kneeling to sit between your heels and sides; lying on your back is to make your feet the bike, raise the pelvis, to sit with legs bent and pressed against the belly knees, rocking on his back, lying on his stomach - swinging on the belly (the boat), alternately by hand to get the other foot, raised feet to breed, to bring and drop.
The implementation of the method is as follows.
3 weeks before surgery on the abdomen are assigned probiotics Bifiform 1 capsule 3 times a day and hilak-Forte 10-15 drops 3 times per day in order to normalize the intestinal microflora. 7 days prior to laparoscopy child electrophoresis is carried out with a proteolytic enzyme iruxol on the anterior abdominal wall of the abdomen, with the aim of hydrolytic decomposition of the protein components of adhesions and prevent bacterial infection and inside is assigned sorbent smecta 1 packet 3 times a day for enterosorption to prevent microbial autocannibalism body. Then performed surgery on the abdomen in laparoscopic dissection of adhesions. In the postoperative period on the first day after surgery assign electrophoresis with a proteolytic enzyme iruxol on the anterior wall of the abdomen for 7 days; from the 2nd or 3rd day, when you get to the intestinal peristalsis, n who appoints inside the sorbent smecta 1 packet 3 times a day for 7 days, from the 8th day after surgery, prescribe probiotics - Bifiform 1 capsule 3 times a day and hilak-Forte 10-15 drops 3 times a day for 1 month. Then a month after laparoscopy assign electrophoresis with a proteolytic enzyme collision on the anterior wall of the stomach up to 8-10 procedures for lysis of connective tissue (adhesions) with simultaneous belly massage and exercise therapy in the form of walk - Proprieta, and then realizing highly knees; on his knees to sit between your heels and sides, lying on his back doing legs the bike, to understand the pelvis, to sit with legs bent and pressed against the belly knees, rocking on his back, lying on his stomach - swinging on the belly (the boat), alternately by hand to get the other foot, raised feet to breed, to bring and drop - in for 8-10 days.
For empirical evidence for the effectiveness of the proposed method were treated with 16 children with adhesive intestinal obstruction after previous surgical interventions on the organs of abdominal cavity. After 6 months was filmed diagnosis SB in 15 children. Recurrence occurred in 1 child. During the observation period from 1 year to 2 years recurrence SAT at children treated there. All children treatment was well tolerated, side effects are not checked.
The inventive method of treatment SAT abdominal cavity in children leads to recovery in 92% of cases and reduce relapses d is 8%, non-invasive, available for in polyclinic conditions, economical, because laparoscopic intervention significantly reduces the length of hospitalization.
1. Patient U., 15 years, survey map No. 8, has complained of periodic, paroxysmal pain in the abdomen. From the anamnesis it is known that in 1992 laparotomy was about closed trauma of the abdomen.
When examining CCS abdominal cavity to the right of the postoperative scar (location drainage) is visualized loop of intestine, papanna to the aponeurosis; and epigastric - papanna intestine to postoperative scar. Given the clinic and data CCS was diagnosed with Adhesive intestinal obstruction (SAT). 3 weeks before surgery were assigned probiotics Bifiform 1 capsule 3 times a day and hilak-Forte 15 drops 3 times a day. 7 days prior to laparoscopy assigned electropores with a proteolytic enzyme iruxol on the anterior wall of the stomach and into the sorbent smecta 1 packet 3 times a day. After that performed laparoscopy with division of adhesions. In the postoperative period on the first day appointed electrophoresis with iruxol on the anterior wall of the abdomen within 7 days from the 2nd day smectite inside 1 package 3 times a day for 7 days, from the 8th day after the operation n is meant Bifiform 1 capsule 3 times a day and hilak-Forte 15 drops 3 times a day for 1 month. A month after laparoscopy performed electrophoresis with collision on the anterior wall of the abdomen in the form of 10 procedures and within 10 days - belly massage and exercise therapy - walking with highly raised legs, kneeling to sit between your heels and sides; lying on the back - lifting pelvis, rocking on the back, “bike”, to sit with your knees bent; lying on his stomach - swinging (boat) and breeding, svidanie and lowering of the raised leg. At follow-up 6 months after laparoscopy child no complaints and according to control RCS adhesions in the abdominal cavity is not revealed.
2. Patient K., aged 15, map survey No. 12, enrolled in a planned manner with complaints of recurrent pain in the lower abdomen. From the anamnesis it is known that in October 2001 performed a laparoscopy in occasion of torsion of a cyst of the left ovary. During examination of the child revealed adhesions in the abdominal cavity. Started preparation for the planned laparoscopy, adhesiolysis. 3 weeks before hirurgicheskogo
intervention appointed Bifiform 1 capsule 3 times a day and hilak-Forte 15 drops 3 times a day. 7 days prior to laparoscopy assigned electrophoresis with iruxol on the anterior wall of the abdomen and inside smectite 1 packet 3 times a day. After that performed laparoscopy with division of adhesions and additional excision old is th postoperative scar with the subsequent imposition of intradermal suture. The postoperative period was uneventful, with 1 day after surgery scheduled electrophoresis with iruxol on the anterior wall of the abdomen within 7 days; 2 days appointed smectite 1 packet 3 times a day for 7 days; 8-th day after the operation assigned Bifiform 1 capsule 3 times a day and hilak-Forte 15 drops 3 times a day for 1 month. 1 month after the laparoscopy, the course of electrophoresis with collision on the anterior wall of the abdomen in the amount of 8 procedures and within 8 days - belly massage, and therapeutic exercise - walking Proprieta, lie on your back lifting your pelvis, rocking on the back, the bike legs, lying on his stomach - swinging (boat), the procurement arm opposite leg, dilution, mixing and lowering of the raised leg. At follow-up at 3 and 6 months after laparoscopy child had no complaints, and according to the CCS adhesions in the abdominal cavity is not revealed.
A method of treating adhesive disease of the abdominal cavity, including surgical intervention in the form of laparoscopic division of adhesions, electrophoresis of proteolytic enzymes on the anterior abdominal wall, characterized in that 3 weeks before laparoscopic dissection of adhesions prescribe probiotics Bifiform 1 capsule and hilak-Forte 10-15 drops 3 times a day, for 7 days before surgery conducted 7 sessions electrophore is and erukala and assign the sorbent smecta 1 packet 3 times a day, conduct laparoscopic dissection of adhesions after surgical intervention within 7 days of conducting electrophoresis with iruxol, after the appearance of intestinal peristalsis appoint sorbent smecta 1 packet 3 times a day for 7 days, from the 8th day after surgery appoint Bifiform 1 capsule and hilak-Forte 10-15 drops 3 times a day for 1 month after 1 month after laparoscopy assign electrophoresis with collision to 8-10 procedures with simultaneous massage of the abdomen and physical therapy complex for 8-10 days.
FIELD: medical engineering.
SUBSTANCE: device has container for keeping product to be applied, dosing unit for distributing the product, power supply element placed near the dosing unit. The dosing unit is designed as rotating element and is apiece of felt. Container walls are flexible. The dosing unit is manufactured from electric conducting material and connected to the power supply element.
EFFECT: enhanced effectiveness in carrying out viscous product iontophoresis.
8 cl, 7 dwg
FIELD: medicine, gynecology, pharmacology, pharmaceutical industry.
SUBSTANCE: invention proposes a preparation that comprises bacterial mass of live microorganisms as an active component, protecting medium and fat base. The preparation comprises lactobacilli as bacterial mass and one or some eubiotic microorganisms taken among the following group: bifidobacteria, streptococci and lactococci taken in the amount per a single dose. Also, the preparation comprises additionally an acceptable sorbent and a biologically active supplement. Also, invention relates to a method for preparing this preparation that involves preparing firstly lactobacilli bacterial mass and one or some genus of eubiotic microorganisms taken among the following group: bifidobacteria, streptococci and lactococci. Then the prepared bacterial mass of microorganisms is immobilized on sorbent used in medicine in its ratio to bacterial mass of microorganisms = (9-1):(1-9) followed by addition of the protecting medium and biologically active supplement to formed mass in the necessary amount. Also, invention describes a method for prophylaxis and treatment of bacterial vaginitis that involves intravaginal administration of the preparation described above in the amount 1-3 doses, 1-3 times per 24 h. The treatment course is prescribed individually. Invention provides expanding assortment of agents used for treatment of bacterial vaginitis. Invention can be used in obstetric-gynecological practice.
EFFECT: improved method for vaginitis treatment, valuable medicinal properties of preparation.
13 cl, 4 tbl, 1 ex
FIELD: medicinal microbiology, biotechnology.
SUBSTANCE: invention relates to a method for assay of specific activity of probiotics and industrial strains that involves determination of the amount of viable microorganisms. The level of viable microorganisms are determined by their adhesive capacity activity with respect to human erythrocytes. Method provides reducing time for assay of the specific activity up to 2-3 h and with using available reagents. Invention can be used as the express-method for estimation of the level of the specific activity (amount of live microorganisms in the preparation dose) of probiotics of different medicinal formulations (lyophilized biomass, tablet and suppository), and industrial strains by the level of their adhesive activity.
EFFECT: improved method for estimation.
3 cl, 5 tbl, 8 ex
FIELD: biotechnology, food industry, medicine, microbiology.
SUBSTANCE: invention relates to the strain that can be used in prophylaxis and/or treatment of diarrhea-associated diseases. The strain Lactobacillus paracasei CNCM I-2116 (NCC 2461) is able to attach to mammal intestine mucosa tissue and to grow in the presence of bile acid salts in their concentrations up to 0.4% and to prevent infection of intestine epithelial cells by rotaviruses. A foodstuff comprises from 1 x 105 to 1 x 1012 CFU of the strain L. paracasei I-2116 (NCC 2461)/g of a food carrier taken among milk, yogurt, curd, cheese, dry milk, children's nutrition and so on. Pharmaceutical composition contains the effective amount of CFU of the strain L. paracasei CNCM I-2116 (NCC 2461) or supernatant of its culture and physiologically acceptable carrier. Invention provides the high level of activity against SA-11 of serotype 3 and rotavirus Hochi of serotype 4.
EFFECT: valuable medicinal properties of strain.
4 cl, 9 dwg, 1 tbl, 11 ex
FIELD: medicine, veterinary science, food industry.
SUBSTANCE: invention relates to the preparation-synbiotic eliciting the biological activity. The biologically active preparation comprises the preparation "Laktobakterin" or "Bifidum-bakterin", or "Koli-bakterin", and water-soluble chitosan succinate, and water-soluble antioxidant as special supplements taken in the definite ratio of components of the preparation. Invention provides enhancing effectiveness of preparations based on microorganism cultures and their storage time. Invention can be used as a curative preparation correcting the damaged normal microflora of digestive tract, in therapy of inflammatory processes of urogenital tract and mouth cavity, for enhancing the general resistance of body.
EFFECT: enhanced and valuable properties of preparation.
FIELD: medicine, gastroenterology.
SUBSTANCE: invention relates to methods for treatment of chronic helicobacter pylori-associated gastritis. Method is carried out by monotherapy with the probiotic "Laminolakt" in the dose 3 dragees per 24 h for 1 month. Method provides elimination of Helicobacter pylori cells on the background of activation of the immune response in stomach mucosa by effect on microflora and the colon intestine immune system.
EFFECT: enhanced effectiveness of treatment.
2 tbl, 1 ex
FIELD: biotechnology, microbiology.
SUBSTANCE: the strain Lactobacillus paracasei CNCM I-2116 (Ncc 2461) is able to attach with mammal intestine mucosa and to grow in the presence of up to 0.4% of bile acid salts and to prevent the infection of intestine epithelial cells with rotaviruses. Agent shows the content from 1 x 105 to 1 x 1012 CFU of the strain L. paracasei I-2116 (NCC 2461) and can be used for preparing an agent and foodstuff taken among milk, yogurt, cheese, dry milk, children's nutrition products or a pharmaceutical preparation taken among a liquid bacterial suspension, dry oral supplement, liquid oral supplement, dry product for feeding through a tube or liquid product for feeding through a tube. Invention provides the enhanced viability of the strain in its using and effectiveness in prevention of adhesion to intestine cells and invasion of pathogenic microorganism cells in intestine causing diarrhea. Invention can be used in food industry and medicine in prophylaxis and/or treatment of diarrhea-associated diseases.
EFFECT: valuable medicinal properties of strain and agent.
3 cl, 5 dwg, 7 ex
FIELD: biotechnology, veterinary science, microbiology.
SUBSTANCE: the strain of bacterium Bacillus subtilis VKM B-2287 is isolated from soil. Bacterial cells are gram-positive with aerobic type of respiratory, don't form capsule but form round spores. The strain hydrolyzes glucose, mannitol and lactose but it doesn't ferment sucrose, inositol, sorbitol and maltose, it doesn't form gas in fermentation process and inhibits the growth of staphylococcus, Escherichia coli, enterobacteria, citrobacteria and aeromonas. The strain is used as industrial one for preparing a preparation named by authors as "Subtilis+". The preparation normalizes function of digestive tract in agricultural animals, poultries and fishes and can be used in treatment and prophylaxis of bacterial infections. Invention can be used for preparing the probiotic preparation.
EFFECT: valuable properties of strain and preparation.
1 tbl, 3 ex
FIELD: medicine, surgery, urology.
SUBSTANCE: one should apply bactisporin probiotic preparation introduced per os at 1-10 x 109 microbial cells twice or thrice for 10-20 d in combination with staphylo-proteic-pyocyanic adsorbed (SPPA) vaccine; moreover, the mentioned combination of preparation should be applied, also, for instillation of wounds, serous cavities, cavities of urinary and biliary ducts at the quantity of 1-5 x 109 microbial cells in isotonic sodium chloride solution. The present innovation provides better humoral and cellular immunity to already developed infectious process, moreover, combined application of SPPA vaccine and bactisporin leads to increased body immune response to antigens of associated vaccine at the background of secondary immunodeficient state induced by infectious process.
EFFECT: higher efficiency of therapy.
1 cl, 5 ex, 3 tbl
FIELD: biotechnology, medicinal microbiology.
SUBSTANCE: invention relates, in particular, to a method for preparing nutrient medium used for production of bacteriophages. Nutrient medium for production of bacteriophages contains acidic casein hydrolyzate as a base with hydrolysis degree 0.6-0.7 and vitamins: nicotinic acid, folic acid, calcium pantothenate, riboflavin, thiamine bromide and biotin, and distilled water. Also, invention relates to a method for preparing nutrient medium used for production of bacteriophages involving hydrolysis of natural casein mixed with water using hydrochloric acid under pressure 0.2 ± 0.05 MPa up to attainment of hydrolysis degree 0.6-0.7 being isoprecipitation and treatment with carbon are carried out simultaneously. Invention provide enhancing growth properties of medium and quality of bacteriophages produced and reducing the cost.
EFFECT: improved preparing method.
3 cl, 1 ex
FIELD: biotechnology, medicine, infectious diseases, medicinal microbiology.
SUBSTANCE: invention relates to a composition designated for treatment and prophylaxis of infections caused by Neisseria microorganism that comprises the following components: (a) protein with amino acid sequence similar by 65% and above with the natural Neisseria protein of a single species (the first group of amino acid sequences is given in the text) and/or its fragment consisting of 10 and more amino acids and eliciting antigen properties; (b) the second protein with amino acid sequence similar by 65% and above with the natural Neisseria protein of another species (the second group of amino acid sequences with even numbers is given in the text), and/or its fragment consisting of 10 or more amino acids and eliciting antigen properties; in particular, the second protein represents NspA. The composition comprises additionally adjuvant. The composition is used both a medicinal agent and for manufacturing the medicinal agent. Applying the invention provides enhancing the effectiveness of prophylaxis or treatment due to the universal effect of the composition (vaccine). Invention can be used in medicine for treatment of infections.
EFFECT: valuable medicinal properties of composition.
8 cl, 137 dwg, 5 tbl, 12 ex
FIELD: biotechnology, microbiology, medicine.
SUBSTANCE: invention relates to the strain Lactobacillus paracasei CNCM I-2116 used for diarrhea prophylaxis causing by pathogenic microorganisms. Supernatant of this strain culture elicits ability to prevent colonization of intestine with pathogenic microorganisms causing diarrhea also and this strain is designated for preparing agent used for prophylaxis and/or treatment of disorders associated with diarrhea. Agent for oral administration represents therapeutically effective dose of the strain L. paracasei CNCM I-2116 or supernatant of its culture and acceptable foodstuff. Invention provides the enhanced viability of the strain in its applying and effectiveness in prophylaxis of adhesion to intestine cells and invasion to intestine cells of pathogenic microorganisms causing diarrhea.
EFFECT: valuable medicinal properties of strain.
5 cl, 8 dwg, 10 ex